Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (1419)	9/14/1998 9:26:00 PM
From: Steve Harmon	Respond to of 2742

Walter, The $33 million Pasteur Merieux is paying to Cistron if certain milestones are made is not really a earnings thing yet. What it does is pay for the development of Cistron's flu vaccine adjuvant so that CIST does not have to burn dollars on that indication. Where it becomes a earnings thing is when it gets approved Cistron will make royalties on any sales from the derived flu vaccine adjuvant that PMC sells on the product. With PMC being the world's largest flu vaccine manufacturer this could bring Cistron very good revenues in the future. My sources tell me that Cistron is very excited on the royalty rate received in the Pasteur Merieux deal.... Of course the good thing PMC now brings to the table is increased exposure in the investment community. When PMC shows the results of the current Flu vaccine adjuvant study people will listen as discussed on this board before.